» Articles » PMID: 12391202

Highly Immunogenic and Totally Synthetic Lipopeptides As Self-adjuvanting Immunocontraceptive Vaccines

Overview
Journal J Immunol
Date 2002 Oct 23
PMID 12391202
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we describe the synthesis of various lipopeptides based on the sequence of luteinizing hormone-releasing hormone (LHRH) and report on their abilities to induce Abs against this "self" hormone when inoculated into mice in the absence of additional adjuvant. The peptides consisted of a colinear CD4(+) T helper cell epitope from the L chain of influenza virus hemagglutinin and LHRH, which has B cell epitopes but no T cell epitopes present in its sequence. Lipids were attached either at the N terminus or between the T cell epitope and LHRH, in the approximate center of the peptide. The lipopeptide constructs displayed different solubilities and immunological properties that depended not only on the lipid content but also on the position of attachment of the lipids. Some of these constructs were highly immunogenic, inducing high titers of Ab, which were capable of efficiently sterilizing female mice when administered in saline by s.c. or intranasal routes. The most effective vaccines were highly soluble, contained the dipalmitoyl-S-glyceryl cysteine moiety, and had this lipid attached at the center of the molecule. The relative ability of the lipopeptides to induce an Ab response in the absence of external adjuvant was reflected by their ability to up-regulate the surface expression of MHC class II molecules on immature dendritic cells. These results demonstrate that the composition and position within peptide vaccines of self-adjuvanting lipid groups can influence the ability to induce the maturation of dendritic cells and, in turn, the magnitude of the resulting Ab response.

Citing Articles

Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases.

Gu Y, Yang J, He C, Zhao T, Lu R, Liu J Signal Transduct Target Ther. 2023; 8(1):273.

PMID: 37455272 PMC: 10350459. DOI: 10.1038/s41392-023-01479-4.


TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.

Mantovani S, Oliviero B, Varchetta S, Renieri A, Mondelli M Int J Mol Sci. 2023; 24(9).

PMID: 37175768 PMC: 10178469. DOI: 10.3390/ijms24098065.


Pushing the envelope: Immune mechanism and application landscape of macrophage-activating lipopeptide-2.

Liao D, Su X, Wang J, Yu J, Luo H, Tian W Front Immunol. 2023; 14:1113715.

PMID: 36761746 PMC: 9902699. DOI: 10.3389/fimmu.2023.1113715.


Adjuvant Pam3CSk4 does not improve the immunization against infection in C57BL/6 mice.

de Campos G, Martins Oliveira-Brito P, Guimaraes J, da Costa L, Lazo Chica J, da Silva T PeerJ. 2023; 11:e14778.

PMID: 36743957 PMC: 9897066. DOI: 10.7717/peerj.14778.


Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice.

Ashhurst A, Johansen M, Maxwell J, Stockdale S, Ashley C, Aggarwal A Nat Commun. 2022; 13(1):6972.

PMID: 36379950 PMC: 9665025. DOI: 10.1038/s41467-022-34297-3.